RPRX

Royalty Pharma plc

62.36

Oct 21 • 2:19 PM ET +0.11 (0.18%)

Healthcare Biotechnology USA Large NASD

Peers: LGND HALO INVA VRTX RVMD ALNY BIIB EXEL GILD AMGN

| Held by: VXF VFLO IWR VYM CGDG IHE IWD MTUM IWS GSLC

Index	-
Market Cap	35.86B
Enterprise Value	46.94B
Income	814.79M
Sales	2.54B
Book/sh	15.33
Cash/sh	1.46
Dividend Est.	1.02 (1.64%)
Dividend TTM	0.92 (1.48%)
Dividend Ex-Date	Nov 13, 2026
Dividend Gr. 3/5Y	5.01% 24.01%
Payout	49.40%
Employees	100
IPO	Jun 16, 2020

P/E	33.20
Forward P/E	10.75
PEG	1.01
P/S	14.14
P/B	4.07
P/C	42.84
P/FCF	11.91
EV/EBITDA	29.60
EV/Sales	18.51
Quick Ratio	2.80
Current Ratio	2.80
Debt/Eq	1.31
LT Debt/Eq	1.26
Option/Short	Yes / Yes

EPS (ttm)	1.88
EPS next Y	5.80
EPS next Q	1.18
EPS this Y	10.17%
EPS next Y	8.99%
EPS next 5Y	10.64%
EPS past 3/5Y	163.11% -7.26%
Sales past 3/5Y	2.06% 2.30%
EPS Y/Y TTM	-18.25%
Sales Y/Y TTM	9.99%
EPS Q/Q	-43.58%
Sales Q/Q	16.50%
Earnings	Nov 04 BMO
EPS/Sales Surpr.	3.82% 1.85%

Insider Own	6.32%
Insider Trans	-1.75%
Inst Own	85.71%
Inst Trans	1.53%
ROA	4.27%
ROE	12.36%
ROIC	5.29%
Gross Margin	99.81%
Oper. Margin	62.33%
Profit Margin	32.13%
SMA20	6.78%
SMA50	4.76%
SMA200	19.09%
Trades

Shs Outstand	445.75M
Shs Float	417.15M
Short Float	3.09%
Short Ratio	4.32
Short Interest	12.89M
52W High	64.38 -3.14%
52W Low	35.92 73.63%
Volatility	2.55% 2.15%
ATR (14)	1.37
RSI (14)	66.31
Beta	0.38
Rel Volume	0.54
Avg Volume	2.98M
Volume	1,204,222

Perf Week	5.71%
Perf Month	6.56%
Perf Quarter	5.66%
Perf Half Y	25.42%
Perf YTD	61.39%
Perf Year	66.38%
Perf 3Y	125.61%
Perf 5Y	66.29%
Perf 10Y	-
Recom	1.50
Target Price	66.00
Prev Close	62.25
Price	62.36
Change %	0.18%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-26	Upgrade	UBS	Neutral → Buy	$49
Sep-30-25	Initiated	Goldman	Buy	$42
May-16-25	Initiated	Morgan Stanley	Overweight	$51
Jun-03-24	Downgrade	UBS	Buy → Neutral	$28
Jun-14-22	Resumed	UBS	Buy	$47
May-13-22	Initiated	Scotiabank	Sector Outperform	$53
Apr-27-22	Initiated	Goldman	Buy	$56
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight	$50
Apr-06-22	Resumed	Morgan Stanley	Overweight	$48
Oct-29-21	Upgrade	Citigroup	Neutral → Buy	$50
Jul-30-21	Initiated	Tigress Financial	Buy	$50
Nov-09-20	Upgrade	UBS	Neutral → Buy	$52 → $51
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	UBS	Neutral	$52
Jul-13-20	Initiated	SunTrust	Buy	$56
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight	$51
Jul-13-20	Initiated	JP Morgan	Neutral	$50
Jul-13-20	Initiated	Goldman	Neutral	$47
Jul-13-20	Initiated	Cowen	Outperform	$55
Jul-13-20	Initiated	Citigroup	Neutral	$50

Show Previous Ratings

Oct-16-26 08:00AM	Royalty Pharma declares fourth quarter 2026 dividend (GlobeNewswire)
Oct-09-26 08:50AM	Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026 (GlobeNewswire)
Sep-15-26 04:35PM	Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program (GlobeNewswire)
Sep-11-26 11:36AM	Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? (Quartz)
Sep-09-26 04:05PM	Royalty Pharma to present at upcoming investor conferences (GlobeNewswire)
07:05PM	Loading…
Sep-04-26 07:05PM	Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen (GlobeNewswire) -5.27%
Aug-25-26 02:24PM	MRK, RPRX Stocks Hit 52-Week Highs What Drove Todays Gains? (Stocktwits)
Aug-12-26 04:10PM	Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million (GlobeNewswire)
Aug-06-26 01:11AM	Revolution Medicines Inc (RVMD) (Q2 2026) Earnings Call Highlights: Daraxonrasib Poised to ... (GuruFocus.com)
Aug-05-26 03:01PM	Royalty Pharma PLC (RPRX) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance (GuruFocus.com)
07:19AM	Royalty Pharma: Q2 Earnings Snapshot (Associated Press)
07:00AM	Royalty Pharma reports second quarter 2026 results (GlobeNewswire)
Aug-03-26 08:15AM	Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives (GlobeNewswire)
Jul-22-26 07:05AM	Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune (GlobeNewswire)
Jul-17-26 04:15PM	Royalty Pharma declares third quarter 2026 dividend (GlobeNewswire)
04:15PM	Loading…
Jul-15-26 04:15PM	Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026 (GlobeNewswire)
Jun-04-26 04:15PM	Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
May-07-26 04:15PM	Royalty Pharma to present at upcoming investor conferences (GlobeNewswire)
May-06-26 01:07PM	Royalty Pharma plc Q1 2026 Earnings Call Summary (Moby)
07:29AM	Royalty Pharma: Q1 Earnings Snapshot (Associated Press)
07:00AM	Royalty Pharma reports first quarter 2026 results (GlobeNewswire)
Apr-21-26 01:00PM	Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation (GlobeNewswire)
Apr-17-26 08:30AM	Royalty Pharma Declares Second Quarter 2026 Dividend (GlobeNewswire)
Apr-15-26 04:15PM	Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026 (GlobeNewswire)
Mar-30-26 07:15AM	Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases (GlobeNewswire)
Mar-23-26 07:15AM	Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence (GlobeNewswire)
Mar-17-26 04:01PM	Royalty Pharma Announces Expansion of Leadership Team (GlobeNewswire)
Mar-03-26 07:22PM	Royalty Pharma plc (RPRX) Earns $51 Target as 2026 Growth Outlook Exceeds Expectations (Insider Monkey)
05:24AM	Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule (Insider Monkey)
Mar-02-26 06:50PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
04:01PM	Loading…
04:01PM	Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience (GuruFocus.com)
10:37AM	Zymeworks Q4 Earnings Call Highlights (MarketBeat)
08:30AM	Zymeworks Inc. Q4 2025 Earnings Call Summary (Moby)
07:00AM	Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform (GlobeNewswire)
06:10AM	Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing (GlobeNewswire)
Mar-01-26 04:27AM	TD Cowen Lifts PT on Royalty Pharma Plc (RPRX) to $50 from $45, Here's Why (Insider Monkey)
Feb-26-26 04:15PM	Royalty Pharma to Present at TD Cowen's 46th Annual Health Care Conference (GlobeNewswire)
02:11AM	Revolution Medicines Q4 Earnings Call Highlights (MarketBeat)
Feb-19-26 11:08PM	PTC Therapeutics Q4 Earnings Call Highlights (MarketBeat)
Feb-18-26 12:38AM	5 Insightful Analyst Questions From Royalty Pharma's Q4 Earnings Call (StockStory)
Feb-12-26 09:07PM	Vertex Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
Feb-11-26 02:02PM	Royalty Pharma PLC (RPRX) Q4 2025 Earnings Call Highlights: Strong Growth and Strategic Capital ... (GuruFocus.com)
12:32PM	Royalty Pharma plc Q4 2025 Earnings Call Summary (Moby)
09:52AM	Royalty Pharma Q4 Earnings Call Highlights (MarketBeat)
09:30AM	Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings (Zacks)
07:32AM	Royalty Pharma: Q4 Earnings Snapshot (Associated Press Finance)
07:25AM	Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings (StockStory)
07:00AM	Royalty Pharma Reports Q4 and Full Year 2025 Results (GlobeNewswire)
Feb-10-26 09:15AM	Exploring Analyst Estimates for Royalty Pharma (RPRX) Q4 Earnings, Beyond Revenue and EPS (Zacks)
06:41AM	UBS and Citi Are Bullish on Royalty Pharma Plc (RPRX) - Here's Why (Insider Monkey)
Feb-09-26 10:06PM	What To Expect From Royalty Pharma's (RPRX) Q4 Earnings (StockStory)
Feb-05-26 11:38PM	3 Mid-Cap Stocks We Keep Off Our Radar (StockStory)
10:00AM	Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-04-26 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-24-26 06:37AM	Jim Cramer on Royalty Pharma: "It's a Terrific Company" (Insider Monkey)
Jan-23-26 05:42AM	Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last? (Zacks)
Jan-22-26 08:53PM	Lightning Round: Coherent is a winner, says Jim Cramer (CNBC TV)
Jan-20-26 04:15PM	Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 (GlobeNewswire)
Jan-12-26 12:26PM	Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug (Benzinga)
10:08AM	TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug (Zacks)
08:55AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
07:15AM	Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-11-26 05:15PM	Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo (GlobeNewswire)
Jan-09-26 08:55AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
08:30AM	Royalty Pharma Announces Dividend Increase (GlobeNewswire)
01:52AM	Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal - Stock Soars Overnight (Benzinga)
Jan-07-26 10:37PM	Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX) (StockStory)
Dec-29-25 04:40PM	Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones (GlobeNewswire)
Dec-16-25 07:15AM	Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million (GlobeNewswire)
Dec-12-25 10:47AM	Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance (PR Newswire)
Dec-05-25 09:56AM	Denali Enters Into a $275M Funding Deal With Royalty Pharma (Zacks)
07:05AM	Denali makes $275m funding agreement with Royalty Pharma (Pharmaceutical Business Review)
Dec-04-25 07:10AM	Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement (GlobeNewswire)
Nov-26-25 08:15AM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-24-25 06:12AM	Vaximm and BCME link on oral cancer immunotherapy platform (Pharmaceutical Technology)
Nov-14-25 12:56PM	Eli Lilly Leads Three Stocks Near Buy Points (Investor's Business Daily)
Nov-12-25 11:03PM	Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
Nov-05-25 04:49PM	Analyst Report: Royalty Pharma plc (Morningstar Research) +6.82%
02:03PM	Royalty Pharma PLC (RPRX) Q3 2025 Earnings Call Highlights: Strong Portfolio Growth and ... (GuruFocus.com)
09:30AM	Royalty Pharma (RPRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:25AM	Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:23AM	Royalty Pharma: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Royalty Pharma Reports Third Quarter 2025 Results (GlobeNewswire)
Nov-04-25 07:15AM	Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences (GlobeNewswire)
Nov-03-25 10:34PM	Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2 (StockStory)
10:15PM	What To Expect From Royalty Pharma's (RPRX) Q3 Earnings (StockStory)
Oct-31-25 12:41PM	How Royalty Pharma Prints Cash Without Biotech's Biggest Risks (MarketBeat)
Oct-29-25 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks)
12:02AM	2 Reasons to Avoid RPRX and 1 Stock to Buy Instead (StockStory)
Oct-28-25 01:34PM	1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data (MarketBeat)
12:24PM	What Do Analysts Think About Royalty Pharma Plc (RPRX)? (Insider Monkey)
Oct-17-25 09:10AM	Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains? (Zacks)
08:15AM	Royalty Pharma Declares Fourth Quarter 2025 Dividend (GlobeNewswire)
Oct-14-25 07:45AM	Kailera nets $600M more to advance Zepbound-like obesity drug (BioPharma Dive)
Oct-09-25 04:15PM	Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire)
Oct-08-25 12:10PM	Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-06-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Oct-03-25 08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
Sep-29-25 08:15AM	Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director (GlobeNewswire)
Sep-23-25 07:10PM	Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth (Insider Monkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Urist Marshall	EVP, Research & Investments	Oct 05 '26	Sale	57.10	4,126	235,595	0	Oct 05 05:12 PM
Urist Marshall	Officer	Oct 05 '26	Proposed Sale	57.10	4,126	235,595		Oct 05 04:02 PM
Urist Marshall	EVP, Research & Investments	Sep 28 '26	Sale	57.88	4,126	238,813	4,126	Sep 30 04:32 PM
Urist Marshall	Officer	Sep 28 '26	Proposed Sale	57.88	4,126	238,813		Sep 28 04:09 PM
Hite Christopher	EVP & Chairman, Partnering	Sep 22 '26	Sale	58.53	100,000	5,853,095	270,401	Sep 24 04:10 PM
SCH Investment Partners LLC	Officer	Sep 22 '26	Proposed Sale	58.47	100,000	5,846,972		Sep 22 04:50 PM
Hite Christopher	EVP & Chairman, Partnering	Aug 18 '26	Sale	59.97	100,000	5,997,250	370,401	Aug 19 04:20 PM
SCH Investment Partners LLC	Officer	Aug 18 '26	Proposed Sale	60.12	100,000	6,012,000		Aug 18 04:45 PM
Coyne Terrance P.	EVP & CFO	Aug 13 '26	Sale	58.68	11,002	645,551	0	Aug 17 05:01 PM
Terrance Coyne	Officer	Aug 13 '26	Proposed Sale	58.56	11,002	644,277		Aug 13 04:43 PM
Errol B. De Souza	Former Affiliate	Aug 12 '26	Proposed Sale	57.79	206,352	11,925,082		Aug 12 06:32 PM
Errol B. De Souza	Former Affiliate	Aug 12 '26	Proposed Sale	57.79	125,000	7,223,750		Aug 12 06:28 PM
Urist Marshall	EVP, Research & Investments	Jul 01 '26	Sale	55.88	9,099	508,454	0	Jul 02 04:10 PM
Hite Christopher	EVP & Chairman, Partnering	Jun 30 '26	Sale	56.52	100,000	5,651,813	459,399	Jul 02 04:08 PM
Hite Christopher	EVP & Chairman, Partnering	Jun 30 '26	Sale	56.46	30,000	1,693,658	40,000	Jul 02 04:08 PM
Urist Marshall	Officer	Jul 01 '26	Proposed Sale	55.88	9,099	508,454		Jul 01 04:18 PM
SCH Investment Partners LLC	Officer	Jun 30 '26	Proposed Sale	57.09	100,000	5,709,000		Jul 01 08:24 AM
Urist Marshall	EVP, Research & Investments	Jun 24 '26	Sale	55.18	9,098	502,067	9,099	Jun 25 05:13 PM
Hite Christopher	EVP & Chairman, Partnering	Jun 23 '26	Sale	54.40	150,000	8,159,277	559,399	Jun 25 05:11 PM
Urist Marshall	Officer	Jun 24 '26	Proposed Sale	55.18	9,098	502,067		Jun 24 04:14 PM
Christopher Hite	Officer	Jun 23 '26	Proposed Sale	55.35	30,000	1,660,500		Jun 23 04:48 PM
SCH Investment Partners LLC	Officer	Jun 23 '26	Proposed Sale	54.45	150,000	8,166,766		Jun 23 04:46 PM
Coyne Terrance P.	EVP & CFO	May 26 '26	Sale	53.98	64,399	3,476,116	0	May 28 04:48 PM
Terrance Coyne	Officer	May 26 '26	Proposed Sale	53.86	64,399	3,468,530		May 26 05:49 PM
Urist Marshall	EVP, Research & Investments	May 20 '26	Sale	52.75	13,684	721,838	18,197	May 21 09:20 PM
Urist Marshall	Officer	May 20 '26	Proposed Sale	52.75	13,684	721,837		May 20 04:23 PM
Urist Marshall	EVP, Research & Investments	May 14 '26	Sale	53.06	13,684	726,137	31,881	May 15 04:38 PM
Norden Gregory	Director	May 14 '26	Sale	53.00	3,045	161,385	191,803	May 15 04:37 PM
Norden Gregory	Officer	May 14 '26	Proposed Sale	53.00	3,045	161,385		May 14 05:28 PM
Urist Marshall	Officer	May 14 '26	Proposed Sale	53.06	13,684	726,138		May 14 05:22 PM
Coyne Terrance P.	EVP & CFO	Apr 28 '26	Sale	49.78	34,791	1,731,840	0	Apr 30 05:54 PM
Terrance Coyne	Officer	Apr 28 '26	Proposed Sale	49.54	34,791	1,723,546		Apr 28 05:00 PM
Coyne Terrance P.	EVP & CFO	Apr 01 '26	Sale	48.33	34,791	1,681,512	32,916	Apr 02 05:58 PM
Terrance Coyne	Officer	Apr 01 '26	Proposed Sale	48.49	34,791	1,687,016		Apr 01 04:55 PM
Coyne Terrance P.	EVP & CFO	Mar 23 '26	Sale	45.53	34,791	1,583,989	43,886	Mar 25 05:05 PM
Terrance Coyne	Officer	Mar 23 '26	Proposed Sale	45.61	34,791	1,586,818		Mar 23 04:43 PM
George Lloyd	Officer	Mar 19 '26	Proposed Sale	45.53	36,518	1,662,665		Mar 19 05:12 PM
George Lloyd	Officer	Mar 18 '26	Proposed Sale	45.79	100,462	4,600,155		Mar 18 06:02 PM
Coyne Terrance P.	EVP & CFO	Mar 02 '26	Sale	46.78	34,791	1,627,534	45,761	Mar 04 05:11 PM
George Lloyd	Officer	Mar 04 '26	Proposed Sale	47.43	136,980	6,496,961		Mar 04 04:52 PM
Terrance Coyne	Officer	Mar 02 '26	Proposed Sale	47.47	34,791	1,651,529		Mar 02 05:26 PM
Coyne Terrance P.	EVP & CFO	Feb 23 '26	Sale	45.32	34,791	1,576,606	47,636	Feb 25 04:08 PM
Terrance Coyne	Officer	Feb 23 '26	Proposed Sale	45.47	34,791	1,581,947		Feb 23 05:06 PM
Coyne Terrance P.	EVP & CFO	Feb 03 '26	Sale	42.84	114,954	4,924,997	23,972	Feb 04 05:07 PM
Coyne Terrance P.	EVP & CFO	Feb 02 '26	Sale	42.08	108,424	4,562,905	30,167	Feb 04 05:07 PM
Coyne Terrance P.	EVP & CFO	Feb 04 '26	Sale	43.29	20,163	872,913	22,885	Feb 04 05:07 PM
Terrance Coyne	Officer	Feb 03 '26	Proposed Sale	42.97	135,117	5,805,977		Feb 03 05:31 PM
Terrance Coyne	Officer	Feb 02 '26	Proposed Sale	42.36	108,424	4,592,841		Feb 02 05:28 PM
Urist Marshall	EVP, Research & Investments	Jan 30 '26	Sale	41.09	20,000	821,810	0	Feb 02 04:59 PM
Urist Marshall	EVP, Research & Investments	Jan 23 '26	Sale	40.26	20,000	805,110	20,000	Jan 26 04:10 PM
Coyne Terrance P.	EVP & CFO	Jan 20 '26	Sale	39.35	69,582	2,737,940	36,010	Jan 23 04:48 PM
Urist Marshall	EVP, Research & Investments	Jan 16 '26	Sale	39.52	20,000	790,346	40,000	Jan 20 05:00 PM
Terrance Coyne	Officer	Jan 20 '26	Proposed Sale	39.09	69,582	2,719,960		Jan 20 04:55 PM
Urist Marshall	EVP, Research & Investments	Jan 09 '26	Sale	40.78	20,000	815,634	60,000	Jan 13 05:37 PM
George Lloyd	Officer	Jan 07 '26	Proposed Sale	41.39	495,860	20,523,645		Jan 07 05:03 PM
Coyne Terrance P.	EVP & CFO	Jan 02 '26	Sale	38.42	69,582	2,673,041	39,760	Jan 06 04:18 PM
Urist Marshall	EVP, Research & Investments	Jan 02 '26	Sale	38.48	20,000	769,650	80,000	Jan 06 04:17 PM
Terrance Coyne	Officer	Jan 02 '26	Proposed Sale	38.86	69,582	2,703,957		Jan 02 06:22 PM
Urist Marshall	EVP, Research & Investments	Dec 26 '25	Sale	39.32	20,000	786,380	100,000	Dec 29 04:58 PM
Urist Marshall	EVP, Research & Investments	Dec 19 '25	Sale	38.38	20,000	767,582	120,000	Dec 22 04:09 PM
Lloyd George W.	EVP, Investments & CLO	Dec 17 '25	Sale	38.57	79,346	3,060,280	30,654	Dec 19 05:24 PM
Lloyd George W.	EVP, Investments & CLO	Dec 18 '25	Sale	38.50	30,654	1,180,053	0	Dec 19 05:24 PM
Urist Marshall	EVP, Research & Investments	Dec 16 '25	Sale	38.32	20,000	766,420	140,000	Dec 17 05:43 PM
Coyne Terrance P.	EVP & CFO	Dec 15 '25	Sale	38.36	69,582	2,669,172	43,510	Dec 17 05:39 PM
Sandy Lamm LLC	Officer	Dec 16 '25	Proposed Sale	38.36	160,000	6,137,600		Dec 16 09:41 PM
Terrance Coyne	Officer	Dec 15 '25	Proposed Sale	38.53	69,582	2,680,994		Dec 15 06:22 PM
Urist Marshall	EVP, Research & Investments	Dec 05 '25	Sale	39.15	23,334	913,591	160,000	Dec 09 05:00 PM
Urist Marshall	EVP, Research & Investments	Dec 05 '25	Sale	39.15	18,242	714,224	7,398	Dec 09 05:00 PM
Lloyd George W.	EVP, Investments & CLO	Dec 03 '25	Sale	39.77	110,000	4,375,008	110,000	Dec 05 05:01 PM
Coyne Terrance P.	EVP & CFO	Dec 01 '25	Sale	39.87	69,582	2,773,956	47,260	Dec 03 05:11 PM
Urist Marshall	EVP, Research & Investments	Dec 01 '25	Sale	39.93	23,333	931,633	183,334	Dec 03 05:10 PM
Urist Marshall	EVP, Research & Investments	Dec 01 '25	Sale	39.90	18,242	727,856	25,640	Dec 03 05:10 PM
Terrance Coyne	Officer	Dec 01 '25	Proposed Sale	39.90	69,582	2,776,322		Dec 01 05:53 PM
Urist Marshall	Officer	Dec 01 '25	Proposed Sale	39.90	36,484	1,455,712		Dec 01 05:10 PM
Sandy Lamm LLC	Officer	Dec 01 '25	Proposed Sale	19.93	46,667	930,232		Dec 01 04:48 PM
Coyne Terrance P.	EVP & CFO	Nov 24 '25	Sale	38.55	69,582	2,682,505	51,010	Nov 26 05:01 PM
Terrance Coyne	Officer	Nov 24 '25	Proposed Sale	39.75	69,582	2,765,884		Nov 24 05:24 PM
Lloyd George W.	EVP, Investments & CLO	Nov 19 '25	Sale	38.34	132,426	5,077,627	0	Nov 21 04:55 PM
Lloyd George W.	EVP, Investments & CLO	Nov 19 '25	Sale	38.34	3,000	115,029	0	Nov 21 04:55 PM
George Lloyd	Officer	Nov 19 '25	Proposed Sale	38.65	355,426	13,737,215		Nov 19 05:41 PM
Coyne Terrance P.	EVP & CFO	Nov 17 '25	Sale	39.30	69,594	2,735,329	54,760	Nov 19 04:53 PM
Terrance Coyne	Officer	Nov 17 '25	Proposed Sale	39.16	69,594	2,725,301		Nov 17 05:38 PM

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

FounderMr. Pablo Legorreta

Executive VP & CFOMr. Terrance P. Coyne

Chairman of Partnering & InvestmentsMr. Christopher Hite

Ph.D.Dr. Marshall Jonathan Urist M.D.

Executive Vice President of Partnering & InvestmentsMr. Greg Butz

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RPRX

Royalty Pharma plc

Upgrade your Finviz experience